Browsing Department of Economics by Author "Dalen, Dag Morten"

Now showing items 1-8 of 8

    • Competing with precision: incentives for developing predictive biomarker tests 

      Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune (SAM DP;06/2022, Working paper, 2022-03)
      We study the incentives of drug producers to develop predictive biomarkers, taking into account strategic interaction between drug producers and health plans. For this purpose we develop a two-dimensional spatial framework ...

    • Competing with precision: incentives for developing predictive biomarker tests 

      Brekke, Kurt Richard; Dalen, Dag Morten; Straume, Odd Rune (Peer reviewed; Journal article, 2023)
      We study the incentives of drug producers to develop predictive biomarkers, taking into account strategic interaction between drug producers and health plans. For this purpose, we develop a two-dimensional spatial framework ...

    • Competition matters: uniform vs. indication-based pricing of pharmaceuticals 

      Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune (DP SAM;01/2025, Working paper, 2025-01)
      Pharmaceutical expenditures are rising rapidly, driven in part by the innovation of highly effective but very expensive drug therapies that treat multiple diseases. While these drugs offer substantial health benefits, ...

    • Diffusion of pharmaceuticals : cross-country evidence of anti-TNF drugs 

      Brekke, Kurt Richard; Dalen, Dag Morten; Holmås, Tor Helge (Discussion paper;7/2013, Working paper, 2013-03)
      This paper studies the diffusion of biopharmaceuticals across European countries, focusing on anti-TNF drugs, which are used to treat autoimmune diseases (e.g., rheumatism, psoriasis). We use detailed sales information on ...

    • Paying for pharmaceuticals: uniform pricing versus two-part tariffs 

      Brekke, Kurt Richard; Dalen, Dag Morten; Straume, Odd Rune (Peer reviewed; Journal article, 2022)
      Two-part pricing (the Netflix model) has recently been proposed instead of uniform pricing for pharmaceuticals. Under two-part pricing the health plan pays a fixed fee for access to a drug at unit prices equal to marginal ...

    • The Price of Cost-effectiveness Thresholds 

      Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune (SAM DP;04/2023, Working paper, 2023)
      Health systems around world are increasingly adopting cost-effectiveness (CE) analysis to inform decisions about access and reimbursement. We study how CE thresholds imposed by a health plan for granting reimbursement ...

    • Taking the competitor’s pill: when combination therapies enter pharmaceutical markets 

      Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune (DP SAM;19/2023, Working paper, 2023-11-22)
      We study the competitive effects of combination therapies in pharmaceutical markets, which crucially hinge on the additional therapeutic value of combinatory use of drugs and the therapeutic substitutability with the most ...

    • The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets 

      Brekke, Kurt Richard; Dalen, Dag Morten; Straume, Odd Rune (Peer reviewed; Journal article, 2023)